The Spanish Competition Authority initiates proceedings against two pharmaceutical companies for abuse of dominant position (Leadiant Biosciences Spa / Leadiant Biosciences)

Competition Authority, Spanish

Previous article The Spanish Competition Authority confirms the opening of an investigation against pharmaceutical firms (Leadiant Biosciences Spa / Leadiant Biosciences) Next article The Italian Competition Authority condemns a ticketing and marketing company for committing exclusionary abuse (TicketOne)

22 Dec 2020

The Spanish Competition Authority initiates proceedings against two pharmaceutical companies for abuse of dominant position (Leadiant Biosciences Spa / Leadiant Biosciences)

KEYWORDS

Reference

Spanish Competition Authority, Leadiant Biosciences Spa / Leadiant Biosciences, Press release, 22 December 2020

The CNMC initiates disciplinary proceedings against Leadiant Biosciences Spa and Leadiant Biosciences LTD for alleged practices prohibited by the Antitrust Law* It is investigating a potential abuse of their dominant market position in Spain involving the manufacture and supply of the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Spanish Competition Authority
Spanish Competition Authority (Madrid)

Spain 89 contributions 21690 visits

Quotation

Spanish Competition Authority, The Spanish Competition Authority initiates proceedings against two pharmaceutical companies for abuse of dominant position (Leadiant Biosciences Spa / Leadiant Biosciences), 22 December 2020, e-Competitions December 2020, Art. N° 98542

Visites 91